Magnesium SulphatePhase 3NCT04646876
Mgso4 as Neuroprotective in Post Traumatic Brain Injury
A Phase 3 study testing Magnesium Sulfate in people with Magnesium Sulphate and Traumatic Brain Injury, run by Osama Mohamed Abdelwahab at 1 site in Egypt.
Trial summary
The aim of this study is to assess the potential role of magnesium sulphate (MgSo4) as a neuroprotective agent using the Glasgow outcome scale following moderate and severe traumatic brain injury. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Magnesium Sulphate, Traumatic Brain Injury, Brain
- What is being tested?
- Magnesium Sulfate
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- 2 May 2019to 2 Jun 2020
- Phase
- Phase 3
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- 1) Patients with moderate (GCS = 9-12), or severe (GCS = 3-8) traumatic brain injury.
- 2) Age above 12 years.
- 3) Consenting for treatment within 24 hours of trauma.
Who cannot join
- 1) Non consenting patients.
- 2) Persistent hypotension (BP below 90 / 60) in 1st 24 hours despite measures of resuscitation.
- 3) Significant multisystem association (e.g. cord injury with spinal shock).
- 4) Known case of renal failure
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Assessment Role of Mgso4 as Neuroprotective in Post Traumatic Brain Injury
The aim of this study is to assess the potential role of magnesium sulphate (MgSo4) as a neuroprotective agent using the Glasgow outcome scale following moderate and severe traumatic brain injury.
Read the detailed description
The study is Prospective , Comparative , double-blind , placebo-controlled study with randomization
Patients with post traumatic brain injury either moderate (glasgow coma scale GCS = 9-12) or severe (GCS = 3-8) admitted in one of the neurosurgical ICU of the following centers; kasr El Aini Hospitals, Beni- Suef University Hospital or Beni- Suef General Hospital.
Study design and statistical inferences Patients with traumatic brain injury included in the study will be randomly allocated into one of two equal groups (30 patients each): -
Group (A): will receive MgSo4. Group (B): will receive normal saline as a placebo.
Each patient will receive all other standard management as indicated on individual basis (e.g. Antiepileptics, brain dehydrating measures, antibiotics, ventilatory support, or surgical intervention when deemed necessary).
The Glasgow outcome scale (GOS) will be used to categorize the outcome after 2 months as follows:
- Death
- Persistent vegetative state: Minimal responsiveness
- Severe disability: Conscious but disabled; dependent on others for daily support
- Moderate disability: Disabled but independent; can work in sheltered setting
- Good recovery: Resumption of normal life despite minor deficits
For each patient, the following will be recorded:
- Personal data: name, age, sex, address, tel. No.
- Mode of trauma: fall from height, road traffic accidents, or isolated head trauma.
- Neurological assessment on admission using the Glasgow coma score.
- Associated injuries or neurological deficits.
- Findings of initial CT brain, as well as follow up scans.
- Any previous illness.
Administration :
Administration regimen of Mgso4 will be as following:
Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: 25 mg / kg twice daily for 48 hrs.
In order to avoid Mgso4 toxicity, infusion of the medication (either Mgso4 or placebo) will be abruptly terminated whenever:
- Urine output < 0.5 ml / kg / hour over 4 hours
- Blood urea > 50 mg/ dL .
- Fall of systolic BP < 90 mm Hg.
- Respiratory center depression (respiratory rate less than 12 per minute).
- Cardiac arrhythmia.
- Loss of deep tendon reflexes.
The third supervisor will be responsible for the safety measures of the study, which will be evaluated by continuous monitoring of vital signs, arterial blood pressure (systolic, diastolic), urine output, serum chemistry.
Preparation of the drug:
The medication will be prepared by three assistants other than the researcher, one in each center where the study will be conducted.
For each patient, a set of bottles will be prepared (initial dose, and 4 maintenance doses). After preparation, each set of bottles will be labeled using the same code consisting of letters (A, B, C, D, E, F) and figures (0 to 9). Total number of codes will be 60 which is the total number of patients allocated (A0, A1, A2,....A9\& B0, B1, ......B9\& C1,...C9\& D0-D9\&E0-E9\& F0-F9).
Only the second supervisor will be acquainted with the key of the code, either it is the studied treatment (Mg So4), or normal saline (placebo). He will be responsible for the random allocation of the patients, and instructing the assistants to prepare either the treatment or the placebo, and their subsequent coding. He will not be informed about the results which will be regularly followed by the first supervisor. The key will be kept hidden from the researcher who will be responsible for recording the results. The key will be disclosed only after conclusion of the study and collecting the results in order to operate the statistical analysis.
Each amp of Mgso4 (0.5 gm / 5ml) will be dissolved in 13.5 ml normal saline (at that concentration, Mgso4 will remain chemically stable for 3 months in room air). For simplicity, this will compose a unit and will be labeled as mentioned. So one unit equals 500 mg dissolved in 13.5 ml normal saline. For each patient, the number of units will be calculated according to the body weight. For example, the initial dose or the daily dose of 70 kg patient equals 7 units (70 x 50 = 3500 mg). For this patient, 3 bottles will be prepared on admission, each bottle will be labeled the same as the units, and each bottle will contain 7 units. The first bottle will be given as the initial dose, and the other two bottles will be divided to 4 equal doses, and will be given over the next 48 hrs. For placebo, the same will be done, but only using normal saline. Which is identical to Mgso4 regarding color and aspect.
- Conditions
- Magnesium Sulphate, Traumatic Brain Injury, Brain, Injury
- Being tested
- Magnesium Sulfate, Placebo
- Keywords
- Magnesium, Sulphate, double, blinded, randomized, control, study
- Medical subject headings
- Brain Injuries, Traumatic, Wounds and Injuries
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Magnesium SulfateDrug
Also called Mgso4
Prospective , comparative , double blind study
PlaceboDrug
Also called Saline
Prospective , comparative , double blind study
| Study group | Role | What they receive |
|---|---|---|
| intervention arm ( Group A ) | Active comparator | including 30 patients Group A was given magnesium Sulphate
Administration regimen of Mgso4 was as following:
Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: (25 mg / kg) per dose twice daily for 48 hrs. Receives: Drug: Magnesium Sulfate |
| Placebo arm (Group B ) | Placebo comparator | including 30 patients Placebo control study Group B was given saline as a placebo. with the same regimen and route of administration of magnesium sulphate Receives: Drug: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glasgow outcome scale after 2 months
assessment of conscious level of the patients after 60 days of drug administration
The Glasgow outcome scale (GOS) has been used to categorize the outcome after 2 months as follows:
- Death.
- Persistent vegetative state: Minimal responsiveness.
- Severe disability: Conscious but disabled; dependent on others for daily support.
- Moderate disability: Disabled but independent; can work in sheltered setting.
- Good recovery: Resumption of normal life despite minor deficits.
Better score means that the patient conscious level is improved
Measured: 60 days from drug administration
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Nov 2020
- Study start2 May 2019
- Primary completion12 Mar 2020
- Study completion2 Jun 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Magnesium SulphateStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- 2 groups, comparative
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Outcomes assessor
- Enrolment
- 60 participants (actual)
Sponsor and investigators
- Lead sponsor
- Osama Mohamed Abdelwahab
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Osama Mohamed Abdelwahab, Cairo University
- Investigators
- Osama Awahab, professor, Principal investigator, Faculty Of Medicine , Beni Suef University , Egypt
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04646876
- Sponsor's protocol ID
- N-142-2019
- Status last verified
- Nov 2020
- First submitted
- 22 Feb 2020
- Last updated
- 30 Nov 2020
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Nov 2020. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessment Role of Mgso4 as Neuroprotective in Post Traumatic Brain Injury
- ClinicalTrials.gov ID
- NCT04646876
- Acronym / sponsor ID
- N-142-2019
- Conditions
- Magnesium Sulphate, Traumatic Brain Injury, Brain, Injury
- Keywords
- Magnesium, Sulphate, double, blinded, randomized, control, study
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 60 participants (actual)
- Lead sponsor
- Osama Mohamed AbdelwahabUniversity, hospital or other
- Study start
- 2 May 2019 (actual)
- Primary completion
- 12 Mar 2020 (actual)
- Study completion
- 2 Jun 2020 (actual)
- First posted
- 30 Nov 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of this study is to assess the potential role of magnesium sulphate (MgSo4) as a neuroprotective agent using the Glasgow outcome scale following moderate and severe traumatic brain injury.
Detailed description
The study is Prospective , Comparative , double-blind , placebo-controlled study with randomization
Patients with post traumatic brain injury either moderate (glasgow coma scale GCS = 9-12) or severe (GCS = 3-8) admitted in one of the neurosurgical ICU of the following centers; kasr El Aini Hospitals, Beni- Suef University Hospital or Beni- Suef General Hospital.
Study design and statistical inferences Patients with traumatic brain injury included in the study will be randomly allocated into one of two equal groups (30 patients each): -
Group (A): will receive MgSo4. Group (B): will receive normal saline as a placebo.
Each patient will receive all other standard management as indicated on individual basis (e.g. Antiepileptics, brain dehydrating measures, antibiotics, ventilatory support, or surgical intervention when deemed necessary).
The Glasgow outcome scale (GOS) will be used to categorize the outcome after 2 months as follows:
- Death
- Persistent vegetative state: Minimal responsiveness
- Severe disability: Conscious but disabled; dependent on others for daily support
- Moderate disability: Disabled but independent; can work in sheltered setting
- Good recovery: Resumption of normal life despite minor deficits
For each patient, the following will be recorded:
- Personal data: name, age, sex, address, tel. No.
- Mode of trauma: fall from height, road traffic accidents, or isolated head trauma.
- Neurological assessment on admission using the Glasgow coma score.
- Associated injuries or neurological deficits.
- Findings of initial CT brain, as well as follow up scans.
- Any previous illness.
Administration :
Administration regimen of Mgso4 will be as following:
Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: 25 mg / kg twice daily for 48 hrs.
In order to avoid Mgso4 toxicity, infusion of the medication (either Mgso4 or placebo) will be abruptly terminated whenever:
- Urine output < 0.5 ml / kg / hour over 4 hours
- Blood urea > 50 mg/ dL .
- Fall of systolic BP < 90 mm Hg.
- Respiratory center depression (respiratory rate less than 12 per minute).
- Cardiac arrhythmia.
- Loss of deep tendon reflexes.
The third supervisor will be responsible for the safety measures of the study, which will be evaluated by continuous monitoring of vital signs, arterial blood pressure (systolic, diastolic), urine output, serum chemistry.
Preparation of the drug:
The medication will be prepared by three assistants other than the researcher, one in each center where the study will be conducted.
For each patient, a set of bottles will be prepared (initial dose, and 4 maintenance doses). After preparation, each set of bottles will be labeled using the same code consisting of letters (A, B, C, D, E, F) and figures (0 to 9). Total number of codes will be 60 which is the total number of patients allocated (A0, A1, A2,....A9\& B0, B1, ......B9\& C1,...C9\& D0-D9\&E0-E9\& F0-F9).
Only the second supervisor will be acquainted with the key of the code, either it is the studied treatment (Mg So4), or normal saline (placebo). He will be responsible for the random allocation of the patients, and instructing the assistants to prepare either the treatment or the placebo, and their subsequent coding. He will not be informed about the results which will be regularly followed by the first supervisor. The key will be kept hidden from the researcher who will be responsible for recording the results. The key will be disclosed only after conclusion of the study and collecting the results in order to operate the statistical analysis.
Each amp of Mgso4 (0.5 gm / 5ml) will be dissolved in 13.5 ml normal saline (at that concentration, Mgso4 will remain chemically stable for 3 months in room air). For simplicity, this will compose a unit and will be labeled as mentioned. So one unit equals 500 mg dissolved in 13.5 ml normal saline. For each patient, the number of units will be calculated according to the body weight. For example, the initial dose or the daily dose of 70 kg patient equals 7 units (70 x 50 = 3500 mg). For this patient, 3 bottles will be prepared on admission, each bottle will be labeled the same as the units, and each bottle will contain 7 units. The first bottle will be given as the initial dose, and the other two bottles will be divided to 4 equal doses, and will be given over the next 48 hrs. For placebo, the same will be done, but only using normal saline. Which is identical to Mgso4 regarding color and aspect.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, outcomes assessor)
- Number of arms
- 2
- Model description
- 2 groups, comparative
| Arm | Type | Receives |
|---|---|---|
| intervention arm ( Group A ) | Active comparator | Drug: Magnesium Sulfateincluding 30 patients Group A was given magnesium Sulphate Administration regimen of Mgso4 was as following: Initial dose: within 24 hrs of trauma 50 mg / kg / IV infusion over 1 hour. Maintenance dose: (25 mg / kg) per dose twice daily for 48 hrs. |
| Placebo arm (Group B ) | Placebo comparator | Drug: Placeboincluding 30 patients Placebo control study Group B was given saline as a placebo. with the same regimen and route of administration of magnesium sulphate |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (3 listed)
- 1) Patients with moderate (GCS = 9-12), or severe (GCS = 3-8) traumatic brain injury.
- 2) Age above 12 years.
- 3) Consenting for treatment within 24 hours of trauma.
Key exclusion criteria (4 listed)
- 1) Non consenting patients.
- 2) Persistent hypotension (BP below 90 / 60) in 1st 24 hours despite measures of resuscitation.
- 3) Significant multisystem association (e.g. cord injury with spinal shock).
- 4) Known case of renal failure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Magnesium SulfateAlso: Mgso4Prospective , comparative , double blind study | Drug | intervention arm ( Group A ) |
| PlaceboAlso: SalineProspective , comparative , double blind study | Drug | Placebo arm (Group B ) |
Primary outcome
Glasgow outcome scale after 2 months
Time frame: 60 days from drug administration
assessment of conscious level of the patients after 60 days of drug administration The Glasgow outcome scale (GOS) has been used to categorize the outcome after 2 months as follows: 1. Death. 2. Persistent vegetative state: Minimal responsiveness. 3. Severe disability: Conscious but disabled; dependent on others for daily support. 4. Moderate disability: Disabled but independent; can work in sheltered setting. 5. Good recovery: Resumption of normal life despite minor deficits. Better score means that the patient conscious level is improved
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Nov 2020.
Related trials for Magnesium Sulphate
Not yet recruiting
Magnesium Sulphate as an Adjuvant in Combined Costoclavicular Block and Suprascapular Block Versus Interscalene Block for Ambulatory Shoulder Arthroscopy
Postoperative Pain, Shoulder Arthroscopy
Active, not recruitingObservational study
The Effect of Magnesium on Post-spinal Headaches
Post-spinal Headache
Not yet recruitingPhase 4
Two Doses of IV Magnesium Sulfate for Prevention of Post-Spinal Shivering
Post Spinal Anesthesia Shivering
Not yet recruitingPhase 4
Biomarkers in Management of Post Partum Preeclampsia
Preeclampsia Severe, Preeclampsia Postpartum
Not yet recruiting
Magnesium Alloy Scaffold With Controlled Degradation for Periarticular Bone Defects
Periarticular Bone Defect, Proximal Humerus Fracture
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Osama Awahab, professor principal investigator
Faculty Of Medicine , Beni Suef University , Egypt
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Magnesium Sulfate in people with Magnesium Sulphate and Traumatic Brain Injury, run by Osama Mohamed Abdelwahab at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Nov 2020. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glasgow outcome scale after 2 months (time frame: 60 days from drug administration). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Nov 2020.